Inhibition of galectin‐3 augments the antitumor efficacy of PD‐L1 blockade in non‐small‐cell lung cancer

Inhibition of galectin‐3 augments the antitumor efficacy of PD‐L1 blockade in non‐small‐cell lung cancer

Multiple clinical trials have shown that monoclonal antibodies (mAbs) against programmed death‐ligand 1 (PD‐1/PD‐L1) can benefit patients with lung cancer by increasing their progression‐free survival and overall survival. However, a significant proportion of patients do not respond to anti‐PD‐1/PD‐...

Full description

Bibliographic Details
Main Authors: Hongxin Zhang, Pengfei Liu, Yan Zhang, Lujun Han, Zhihui Hu, Ziqi Cai, Jianhui Cai
Format: Article
Language:English
Published: Wiley 2021-03-01
Series:FEBS Open Bio
Subjects:
galectin‐3
immunotherapy
lung cancer
NSCLC
PD‐L1
tumor
Online Access:https://doi.org/10.1002/2211-5463.13088

Internet

https://doi.org/10.1002/2211-5463.13088

Similar Items